Announcements Trials

Browse Landscape

Phase

Status

Completed 4 Recruiting 3 Terminated 2 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Serotonin Syndrome 1 Carcinoid Heart Disease 1

Interventions

Cisplatin 22 Carboplatin 15 Radiotherapy 13 Paclitaxel 11 Gemcitabine 10 Rituximab 9 Fluorouracil 9 Drug Therapy 6 Dexamethasone 5 Cyclophosphamide 5 Capecitabine 5 Bevacizumab 5 Vinorelbine 4 Pemetrexed 4 Nivolumab 4 Methotrexate 4 Etoposide 4 Docetaxel 4 Bendamustine Hydrochloride 4 spartalizumab 3 pertuzumab 3 pembrolizumab 3 fludarabine 3 Vincristine 3 Trastuzumab 3 Surgical Procedures, Operative 3 Standard of Care 3 Prednisone 3 Oxaliplatin 3 Lenalidomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Withdrawn × lanreotide × Clear all

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡